This is the authors' abstract. We don't add key points for this paper.
BACKGROUNDUse of surgicaladjuvantchemotherapyemployinga combination of cytotoxic drugs, e.g.CMF (cyclophosphamide/methotrexate/5-fluorouracil)-type regimens, in certain subsets of patients with axillary lymph node-negative breast cancer has been established internationally by consensus, based on data obtained from large-scaleclinical trials and their meta-analysis (1,2).Japan has long had a unique standpointon this issue.There are two prominent views on the evaluation of postoperative chemotherapy for breast cancer patients.The first view is that breast cancerin Japanesewomenis biologicallylessaggressive than that in Caucasianwomen.Evidencesupportingthisviewis that5-year disease-freesurvivalrate in Japanesenode-negative breastcancer patients is -90%, which is apparentlybetter thanthat observedin
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Toru Watanabe (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: